Literature DB >> 25262788

New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study.

M A Fadel1, A A Tawfik.   

Abstract

BACKGROUND: Hidradenitis suppurativa (HS), is a chronic, recurrent dermatosis affecting skin that contains apocrine glands. Photodynamic therapy using aminolaevulinic acid (ALA) activated by intense pulsed light (IPL) have shown variable success rates, with some adverse effects. AIMS: To evaluate the efficacy and safety of methylene blue (MB) as a photosensitizer delivered as a niosomal gel for the treatment of HS using IPL.
METHODS: We enrolled 11 patients with HS in the study, which was a randomized split-body study. One side of each patient's body was treated with niosomal MB (NMB) gel and the other side was treated with unloaded (free) MB (FMB) gel. The affected sites were irradiated using IPL with a 630 nm filter. Patients were followed up at 1, 3 and 6 months after treatment.
RESULTS: Drug release from the FMB gel was significantly higher (P > 0.05) than from the NMB gel. Lesions showed 77.3% and 44.1% reduction on the NMB and FMB sides, respectively. A significant reduction in the Hidradenitis Suppurativa Lesion, Area and Severity Index (HS-LASI) after treatment was elicited in both groups, with no pain, erythema or hyperpigmentation.
CONCLUSION: The combination of MB as a photosensitizer activated with 630 nm IPL as a light source is a successful PDT for HS. Delivery of MB in niosomes was more effective for drug penetration to the dermis compared with delivery by FMB gel. The 630 nm filter was not only a source of activation of MB but also a means of hair-follicle destruction.
© 2014 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25262788     DOI: 10.1111/ced.12459

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  6 in total

Review 1.  Photodynamic Therapy and Skin Appendage Disorders: A Review.

Authors:  Matteo Megna; Gabriella Fabbrocini; Claudio Marasca; Giuseppe Monfrecola
Journal:  Skin Appendage Disord       Date:  2016-12-08

2.  An insight into photodynamic therapy towards treating major dermatological conditions.

Authors:  Anuradha Dey; Gautam Singhvi; Anu Puri; Prashant Kesharwani; Sunil Kumar Dubey
Journal:  J Drug Deliv Sci Technol       Date:  2022-08-30       Impact factor: 5.062

Review 3.  North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management.

Authors:  Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin
Journal:  J Am Acad Dermatol       Date:  2019-03-11       Impact factor: 15.487

Review 4.  Interventions for hidradenitis suppurativa.

Authors:  John R Ingram; Pick-Ngor Woo; Ser Ling Chua; Anthony D Ormerod; Nemesha Desai; Anneke C Kai; Kerry Hood; Tara Burton; Francisco Kerdel; Sarah E Garner; Vincent Piguet
Journal:  Cochrane Database Syst Rev       Date:  2015-10-07

Review 5.  Interventions for hidradenitis suppurativa: a Cochrane systematic review incorporating GRADE assessment of evidence quality.

Authors:  J R Ingram; P N Woo; S L Chua; A D Ormerod; N Desai; A C Kai; K Hood; T Burton; F Kerdel; S E Garner; V Piguet
Journal:  Br J Dermatol       Date:  2016-03-30       Impact factor: 9.302

Review 6.  Antimicrobial Photodynamic Therapy: Latest Developments with a Focus on Combinatory Strategies.

Authors:  Raphaëlle Youf; Max Müller; Ali Balasini; Franck Thétiot; Mareike Müller; Alizé Hascoët; Ulrich Jonas; Holger Schönherr; Gilles Lemercier; Tristan Montier; Tony Le Gall
Journal:  Pharmaceutics       Date:  2021-11-24       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.